Professor Alan Boyd began his 30 years’ pharmaceutical career with Glaxo Group Research Ltd. From 1988 he led ICI’s cardiovascular medical research team, later assuming the role of Director of Clinical and Medical Affairs at ICI Pharma, Canada.
In 1999, after four years as Head of Medical Research for Zeneca Pharmaceuticals, he became Director of Research and Development for Ark Therapeutics Ltd where he was responsible for delivering the majority of key development milestones that have shaped the company. In particular he led the development of their gene based medicines portfolio.
In April 2005, he left to set up Boyd Consultants. The focus of which is to aid and support early stage life-science based companies of the sort of which Ark had its origins. His clients now include many companies in Europe, North America and Japan who are devoted to the development of new medicines.
A graduate in Biochemistry and Medicine from the University of Birmingham, UK, Professor Boyd is also a Fellow, and Chair of the Specialist Advisory Committee in Pharmaceutical Medicine at the Faculty of Pharmaceutical Medicine, Royal College of Physicians, United Kingdom. Alan is the immediate past President of the Faculty, following a three year term which ended in November 2018.
In November 2009 he was appointed an Honorary Professor in the College of Medical and Dental Sciences at the University of Birmingham Medical School, in recognition of his expertise in medicines development.
Crewe Business Park
CW1 6GL, UK
T +44 (0)1270 270010
F +44 (0)1270 253832
M +44 (0)7899 873150
- +44 (0)1270 270010